The treatment intensification cohort had a significantly higher number of patients with de novo metastatic disease (P = .038), a numerically higher number of high-volume disease (P = .094) and higher initial median PSA at time of advanced disease (PSA = 435 vs 64.8 ng/mL) compared with the ADT cohort. Here, KLK3 is linked to metastatic neoplasm.